吡嗪酰胺基因型耐药而非最低抑菌浓度与耐多药结核患者痰培养转阴时间延长相关
该队列研究纳入瑞典1992–2014年157例耐多药结核患者,评估吡嗪酰胺基因型药敏与MIC对痰培养转阴时间及治疗结局的影响。结果显示基因型耐药与转阴时间延长29天相关,而MIC与转阴时间及治疗结局均无关联。快速基因型药敏有助于识别可能从吡嗪酰胺治疗中获益的患者。
要点
- 耐多药结核中吡嗪酰胺基因型耐药与痰培养转阴时间延长29天相关。
- 吡嗪酰胺MIC降低与痰培养转阴时间无显著关联。
- 基因型药敏和MIC均与治疗结局无关。
核心结论
- 在耐多药结核患者中,吡嗪酰胺基因型耐药与痰培养转阴时间延长相关,而MIC与转阴时间及治疗结局无关。
研究设计与样本
- 队列研究纳入瑞典1992–2014年诊断为耐多药结核的157例患者,收集临床、微生物学及治疗数据。
- 采用MIC、表型药敏和pncA、rpsA、panD基因全基因组测序定义吡嗪酰胺耐药,用Cox回归分析。
主要发现
- 157例中56.1%(n=88)为吡嗪酰胺耐药株,49.7%(n=78)接受吡嗪酰胺治疗。
- 吡嗪酰胺MIC和基因型药敏均与治疗结局无关。
临床怎么用
- 快速吡嗪酰胺基因型药敏有助于识别可能从吡嗪酰胺治疗中获益的耐多药结核患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes. Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA resistance, but genotypic DST (gDST) and minimum inhibitory concentration (MIC) could be beneficial. We aimed to assess the impact of PZA gDST and MIC on time to sputum culture conversion (SCC) and treatment outcome in patients with MDR-TB. METHODS: Clinical, microbiological, and treatment data were collected in this cohort study for all patients diagnosed with MDR-TB in Sweden from 1992-2014. MIC, pDST, and whole-genome sequencing of the pncA, rpsA, and panD genes were used to define PZA resistance. A Cox regression model was used for statistical analyses. RESULTS: Of 157 patients with MDR-TB, 56.1% (n = 88) had PZA-resistant strains and 49.7% (n = 78) were treated with PZA. In crude and adjusted analysis (hazard ratio [HR], 0.49; 95% conficence interval [CI], .29-.82; P = .007), PZA gDST resistance was associated with a 29-day longer time to SCC. A 2-fold decrease in dilutions of PZA MIC for PZA-susceptible strains showed no association with SCC in crude or adjusted analyses (HR, 0.98; 95% CI, .73-1.31; P = .89). MIC and gDST for PZA were not associated with treatment outcome. CONCLUSIONS: In patients with MDR-TB, gDST PZA resistance was associated with a longer time to SCC. Rapid PZA gDST is important to identify patients who may benefit from PZA treatment.
引用
- Kuhlin J, Davies Forsman L, Mansjö M, et al. Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis. Clin Infect Dis. 2021. PMID: 33011791. doi:10.1093/cid/ciaa1509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。